| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/10/2011 | CA2485535C Modified release pharmaceutical formulation |
| 05/10/2011 | CA2477890C Immediate release pharmaceutical granule compositions and a continuous process for making them |
| 05/10/2011 | CA2460436C Stabilization of active agents by formulation into nanoparticulate form |
| 05/10/2011 | CA2454976C Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
| 05/10/2011 | CA2431890C Lipid microparticles by cryogenic micronization |
| 05/10/2011 | CA2427899C Microgranules based on active principle and method for making same |
| 05/10/2011 | CA2417806C New immunoeffector compounds |
| 05/10/2011 | CA2394856C Enzyme treatment for infection |
| 05/10/2011 | CA2382560C Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 05/10/2011 | CA2375600C Method for making granules with masked taste and instant release of the active particle |
| 05/05/2011 | WO2011053917A2 Gastroretentive oral high dose zinc preparations |
| 05/05/2011 | WO2011053841A1 Ocular drug delivery devices |
| 05/05/2011 | WO2011053803A2 Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders |
| 05/05/2011 | WO2011053792A2 Methods and compositions for sustained delivery of drugs |
| 05/05/2011 | WO2011053789A2 Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease |
| 05/05/2011 | WO2011053653A2 Prevotella histicola preparations and the treatment of autoimmune conditions |
| 05/05/2011 | WO2011053331A1 Vaccine compositions and methods of use |
| 05/05/2011 | WO2011053265A2 The parmaceutical compositions comprising calcium and vitamin d |
| 05/05/2011 | WO2011053251A1 Fast dissolving solid dosage form |
| 05/05/2011 | WO2011053130A1 Bolus system |
| 05/05/2011 | WO2011053003A2 Gastric-retentive sustained release formulation containing pregabalin, polyethyleneoxide and pva-peg graft copolymer |
| 05/05/2011 | WO2011052884A2 Sustained release tablet containing theobromine |
| 05/05/2011 | WO2011052804A1 Method of delivering agent into target cell |
| 05/05/2011 | WO2011052765A1 Alleviator for renal disorders caused by administration of platinum-containing drug |
| 05/05/2011 | WO2011052706A1 Dry powder inhaler of tranilast having high solubility |
| 05/05/2011 | WO2011052613A1 Cosmetic and external skin preparation, and medical instrument |
| 05/05/2011 | WO2011052500A1 Wax stable formulation |
| 05/05/2011 | WO2011052499A1 Pharmaceutical composition having improved storage stability |
| 05/05/2011 | WO2011052346A1 Pressurized device for generating evenly-diametered vesicles |
| 05/05/2011 | WO2011051971A2 Solid dispersion of rifaximin |
| 05/05/2011 | WO2011051968A2 Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof |
| 05/05/2011 | WO2011051924A2 Method of wound treatment using liquid gallium nitrate |
| 05/05/2011 | WO2011051525A1 System for administering biologically active substances, which comprises poly-ε-caprolactone, poloxamine and one or more active substances |
| 05/05/2011 | WO2011051486A2 Pharmaceutical solution of non covalently bound albumin and acylated insulin |
| 05/05/2011 | WO2011051406A1 Sterilization of biodegradable hydrogels |
| 05/05/2011 | WO2011051155A2 Stable protective coatings for pharmaceutical dosage forms |
| 05/05/2011 | WO2011050961A1 Composition comprising fesoterodine and fiber |
| 05/05/2011 | WO2011050948A1 Tape, in particular adhesive tape, for the treatment of skin disorders comprising a film, in particular dissolvable film, containing at least one enzyme |
| 05/05/2011 | WO2011050947A2 Tape, in particular, adhesive tape, for the treatment of skin disorders comprising at least one hyperkeratosis inhibitor and/or at least one keratinolytic agent |
| 05/05/2011 | WO2011050944A1 Formulations containing celecoxib |
| 05/05/2011 | WO2011050739A1 Submicro emulsion of paclitaxel using steroid complex as intermediate carrier |
| 05/05/2011 | WO2011050735A1 Paclitaxel/steroidal complex |
| 05/05/2011 | WO2011050728A1 Stable composition of rasagiline |
| 05/05/2011 | WO2011050710A1 Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| 05/05/2011 | WO2011050684A1 Pharmaceutical composition for treating tumor |
| 05/05/2011 | WO2011050457A1 Stabilized formulation for oral administration of therapeutic agents and related methods |
| 05/05/2011 | WO2011050388A1 Liquid crystal composition and method of use |
| 05/05/2011 | WO2011017484A3 Sublingual and buccal film compositions |
| 05/05/2011 | WO2011000811A3 Pharmaceutical solutions for infusion |
| 05/05/2011 | WO2010151565A3 Combination therapies for the treatment of obesity |
| 05/05/2011 | WO2010151353A3 Injectable beta-hairpin peptide hydrogel that kills methicillin-resistant staphylococcus aureus |
| 05/05/2011 | WO2010148007A3 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| 05/05/2011 | WO2010128525A8 A formulation of ivabradine for treating the cardiovascular disease |
| 05/05/2011 | WO2010057160A9 Releasable fusogenic lipids for nucleic acids delivery systems |
| 05/05/2011 | WO2010047765A8 Nanostructures for drug delivery |
| 05/05/2011 | WO2010027907A3 Pharmaceutical composition having relatively low ionic strength |
| 05/05/2011 | WO2009071990A3 No-donating cordicosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties |
| 05/05/2011 | US20110105995 Uniform-sized, multi-drug carrying, and photosensitive liposomes for advanced drug delivery |
| 05/05/2011 | US20110105825 Nanoparticle-sized magnetic absorption enhancers having three-dimensional geometries adapted for improved diagnostics and hyperthermic treatment |
| 05/05/2011 | US20110105748 Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds |
| 05/05/2011 | US20110105620 Organic compounds |
| 05/05/2011 | US20110105615 Tablet quickly disintegrating in the oral cavity and method for producing the same |
| 05/05/2011 | US20110105551 Analgesics for nasal administration |
| 05/05/2011 | US20110105391 Methods and Compositions for Delivering Peptides |
| 05/05/2011 | US20110105380 Protection of Nano-Scale Particles from Immune Cell Uptake |
| 05/05/2011 | US20110105333 Seed Treatment Compositions and Methods |
| 05/05/2011 | US20110104362 Method of making a dry powder pharmaceutical composition |
| 05/05/2011 | US20110104296 Endorphin Therapy Compositions and Methods |
| 05/05/2011 | US20110104295 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 05/05/2011 | US20110104294 Magnetic nanocomposite for inhibiting/treating cancer and method for fabricating the same |
| 05/05/2011 | US20110104293 Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors |
| 05/05/2011 | US20110104292 Medical composition and medical kit |
| 05/05/2011 | US20110104291 Formulation of Fine Particles Using Liquefied or Dense Gases |
| 05/05/2011 | US20110104290 Compositions for reducing blood glucose level and uses thereof |
| 05/05/2011 | US20110104289 Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications |
| 05/05/2011 | US20110104288 Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients |
| 05/05/2011 | US20110104287 Fenoldopam formulations and pro-drug derivatives |
| 05/05/2011 | US20110104286 Pharmaceutical compositions containing the enzyme cyprosin, an aspartic peptidase from cynara cardunculus and its inclusion in antitumour formulations |
| 05/05/2011 | US20110104285 Process for the manufacture of a pharmaceutical product |
| 05/05/2011 | US20110104284 Hyaluronic acid derivative based three-dimensional matrix |
| 05/05/2011 | US20110104283 Compositions and methods of natural products in nanoformulations for the prevention and treatment of osteoporosis |
| 05/05/2011 | US20110104282 New Therapy of Treatment of the Irritable Bowel Syndrome |
| 05/05/2011 | US20110104281 Method for treating pain using a substituted 2-aminotetralin compound |
| 05/05/2011 | US20110104280 Wound treatment systems, devices, and methods using biocompatible synthetic hydrogel compositions |
| 05/05/2011 | US20110104279 Healing powder and method of use thereof |
| 05/05/2011 | US20110104278 Bone tissue substitute, a solidifiable bone precursor and method of making same |
| 05/05/2011 | US20110104277 Oxygen barrier film coatings for pharmaceutical dosage forms |
| 05/05/2011 | US20110104276 Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
| 05/05/2011 | US20110104275 Methods and kits for treating cluster headache disorders |
| 05/05/2011 | US20110104274 Novel composition and uses thereof, in particular cosmetic uses, for treating skin dehydration |
| 05/05/2011 | US20110104273 Gastric retentive pharmaceutical compositions for immediate and extended release of phenylephrine |
| 05/05/2011 | US20110104272 Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine |
| 05/05/2011 | US20110104271 Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients |
| 05/05/2011 | US20110104270 Process for production of spherical microparticles comprising tamsulosin hydrochloride |
| 05/05/2011 | US20110104269 Compositions for the oral delivery of corticosteroids |
| 05/05/2011 | US20110104268 Galenic applications of self-emulsifying mixtures of lipidic excipients |
| 05/05/2011 | US20110104267 Pharmaceutical compositions of antiretrovirals |
| 05/05/2011 | US20110104266 Multimicroparticulate pharmaceutical forms for oral administration |
| 05/05/2011 | US20110104265 Compositions and methods of targeted nanoformulations in the management of osteoporosis |
| 05/05/2011 | US20110104264 Gastric acid secretion inhibiting composition |